A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
for Solid Tumors
Drug: INCB161734
16 locations incl. Phoenix
Sponsor: Incyte Corporation
Sex: All·Age: 18+
Code: NCT06179160·Phase 1·Recruiting